Published in BMC Cancer on June 04, 2013
DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer. World J Gastroenterol (2014) 0.89
An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese. Oncotarget (2016) 0.82
Protein interactome of muscle invasive bladder cancer. PLoS One (2015) 0.82
BcCluster: A Bladder Cancer Database at the Molecular Level. Bladder Cancer (2016) 0.76
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? Investig Clin Urol (2016) 0.76
Gene-specific promoter methylation is associated with micronuclei frequency in urothelial cells from individuals exposed to organic solvents and paints. J Expo Sci Environ Epidemiol (2015) 0.75
Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. Int J Mol Sci (2017) 0.75
Non-blood circulating tumor DNA detection in cancer. Oncotarget (2017) 0.75
Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. J Cancer Res Clin Oncol (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
DNA hypomethylation in cancer cells. Epigenomics (2009) 3.71
High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A (2007) 2.10
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Urine markers for bladder cancer surveillance: a systematic review. Eur Urol (2005) 1.90
A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res (2007) 1.77
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol (2004) 1.39
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res (2002) 1.36
What we could do now: molecular pathology of bladder cancer. Mol Pathol (2001) 1.22
The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer (2009) 1.16
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res (2007) 1.05
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res (2008) 1.05
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene (2006) 0.99
DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol (2002) 0.98
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer (2006) 0.97
Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest (2005) 0.96
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res (2004) 0.95
DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer (2008) 0.94
Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. PLoS One (2012) 0.93
Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol (2006) 0.92
Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol (2006) 0.87
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology (2009) 2.23
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res (2007) 2.21
Cell adhesion system and human cancer morphogenesis. Cancer Sci (2003) 2.18
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun (2003) 2.01
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology (2009) 1.86
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer (2003) 1.75
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun (2008) 1.74
Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A (2002) 1.73
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2008) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol (2009) 1.66
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res (2007) 1.65
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer (2009) 1.64
Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol (2004) 1.64
Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol (2004) 1.63
Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res (2003) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol (2011) 1.58
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol (2007) 1.56
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol (2008) 1.52
OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A (2011) 1.51
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. Urology (2012) 1.49
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res (2011) 1.47
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res (2010) 1.47
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47